Skip to content
value.today

Lite Strategy, Inc.: financial analysis

Ratios worked out from 10 fiscal years of Lite Strategy, Inc.'s statements, compared with 670 companies in Biotechnology.

Return on equity, 2026
-243.0%
Biotechnology: -61.0%

Lite Strategy, Inc. scorecard#

Passes 4 of the 14 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (0 of 3). Fiscal year 2026; market cap of Oct 16, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.9×Price to book 0.9× against Biotechnology's median of 2.8×.
    • ✓Price to sales below its peers' median1.3×Price to sales 1.3× against Biotechnology's median of 8.6×.
    • ✗Free cash flow yield above 5%-57.1%Free cash flow is -57.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.06 vs -2.39Diluted EPS -2.06 in fiscal 2026 against -2.39 the year before (report's currency).
    • ✗Net income higher than five years earlier-$71 M-$71 M in fiscal 2026 against -$41 M in 2021.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$71 MNet income -$71 M in fiscal 2026.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2026.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-243.0%-243.0% in fiscal 2026.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities5.7×Current ratio 5.74 at the end of fiscal 2026.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 2
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year418.7%Diluted shares up 418.7% in fiscal 2026.
    • ✓Dividends and buybacks above 3% of the market value13.4%Dividends and buybacks were 13.4% of the market value.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2026 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Net loss of $71 million.
  • The share count rose 418.7% in the year.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

1of 6(3 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profitno
  • Operations brought in cashno
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin rosenot on file
  • Asset turnover rosenot on file

Profitability#

Lite Strategy, Inc.: profitability by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Gross margin—————74.8%—
Operating margin——22.3%-75.3%-185.5%-60.5%—
Net margin——27.6%-65.6%-132.7%-68.9%—
Return on equity-243.0%-63.8%62.5%-83.1%-106.0%-61.0%9%
Return on assets-233.4%-53.4%22.2%-21.4%-30.7%-44.4%6%

Growth#

Lite Strategy, Inc.: growth by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Revenue growth——33.8%20.0%17.0%15.8%—
Revenue growth, 3 years a year——23.3%20.7%102.2%12.9%—
Revenue growth, 5 years a year——67.7%97.6%11.9%15.4%—

Financial strength#

Lite Strategy, Inc.: financial strength by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Current ratio5.74×13.54×4.88×5.29×6.84×4.39×59%
Equity share of assets97.5%92.6%79.8%20.4%29.5%64.3%99%

Cash#

Lite Strategy, Inc.: cash by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Free cash flow—$-21 M$-50 M$-53 M$-49 M$-40 M—
Free cash flow margin——-77.3%-107.6%-121.0%-61.5%—
Cash conversion——-280.4%——72.6%—
Capital spending share of revenue——0.0%0.1%1.2%1.7%—

Shareholder returns#

Lite Strategy, Inc.: shareholder returns by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Buyback yield13.4%————1.5%95%
Shareholder yield13.4%————1.7%92%
Dividend payout——64.8%——18.6%—
Change in share count418.7%0.0%0.0%6.5%-94.5%17.3%1%

Efficiency#

Lite Strategy, Inc.: efficiency by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Asset turnover——0.81×0.33×0.23×0.26×—

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Buyback yield
Shares bought back in the fiscal year as a share of today's market value.
Shareholder yield
Dividends plus buybacks as a share of today's market value.
Dividend payout
Dividends paid as a share of net income. Only when the year was profitable.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).